Abstract: Natural products found a wide use in folk medicine. Presently, when routine development of new drugs faced a considerable challenge, they become an inspiration and valuable source in drugs discovery. Rather complex and diverse chemical structures of natural compounds provide a basis for modulation of different biological targets. Natural compounds exhibit a multitargeted action that may lead to additive/synergistic or antagonistic effects. Rational design of more safe and potent pharmaceuticals requires an estimation of probable multiple actions of natural products. Our software PASS can perform such estimation. It predicts with reasonable accuracy over 3500 pharmacotherapeutic effects, mechanisms of action, interaction with the metabolic system, and specific toxicity for drug-like molecules on the basis of their structural formulae. We analyzed PASS predictions utilizing PharmaExpert, which performs selection of compounds with multiple mechanisms of action, analysis of activity-activity relationships and drug-drug interactions. The paper describes an application of PASS and PharmaExpert to the evaluation of biological activity of natural compounds including marine sponge alkaloids, triterpenoids of lupane group, and their derivatives. Proposed computer-aided methods can generate combinatorial libraries of macrolides. They help to select the most promising pharmaceutical leads with the required properties. Case study, based on the analysis of biological activity spectra predicted for St John's Wort constituents, clearly demonstrates capabilities of computational methods in the evaluation of multitargeted actions, additive/synergistic and/or antagonistic effects of natural products.
INTRODUCTION
Natural products are widely used in a non-traditional medicine [1] , especially in China [2] , India [3] and Russia [4] . Being created by Mother Nature, natural compounds are specially adapted for their interactions with biological systems [5] ; therefore, they are considered as valuable sources for drug discovery. Over 70% of New Chemical Entities (NCEs) introduced into medical practice in 1981-2006 were obtained on the basis of natural products [6] . Rather complex and diverse chemical structures of natural compounds provide the basis for modulation of different biological targets [7] . Multitargeted actions of natural compounds could lead to additive/synergistic or antagonistic effects [8] . Since there are several thousands of known pharmacological targets and natural products exhibit pleiotropic action interacting with multiple targets, therefore computer-aided methods could be extremely useful for natural products evaluation [9] .
Generally, natural products research requires the utilization of virtual screening methods to find new lead substances. Currently, three main integrated approaches are in use for achieving this purpose, including: (1) creation of 3D structure database of natural product components with description of biological activity obtained from in vitro screening of natural products extracted from ethnopharmacological sources; (2) selection of biologically active material on the basis of hits found by docking in the database of natural product 3D structures; (3) parallel screening of unstudied natural substances, to identify the promising lead compounds [10] . But all these strategies confined to identification of phytochemical lead ethnic biological activity only. It is believed that just a small part of structural diversity exhibited by plant compounds has been seriously explored for its pharmacological potential so far [11] ; and, therefore, new in-silico approaches are necessary to reveal novel biological activities of known natural products, including their interactions with the known biological targets and related pharmacotherapeutic effects. Predicted pharmacological profiling [12] of natural products could be performed with computer program PASS (Prediction of Biological Activity for Substances).
PASS APPROACH
The computer program PASS is the product of ideas that originated some 35 years ago from the development of a National Registration System for New Chemical Compounds in the former USSR [13] . Since all research institutes and universities in the Soviet Union were state-owned, it was intended that all chemists who synthesized new chemical compounds or extracted them from natural sources should register the structural formulae of those compounds, together with the associated information about physico-chemical properties and biological activities. In order to identify probable biological activities and to select the most promising compounds for biological testing there was a proposition that during the registration process, these structures must be analyzed using computer-aided methods.
The first attempts to develop computer-aided methods for the prediction of biological activity from chemical structures were made in the 1970s [14, 15] . Further progress was made in the following decade [16] [17] [18] [19] , but for various reasons the problem was not completely solved at that time. However, the obtained experience had provided the basis for the later development of PASS [20, 21] .
From the beginning, PASS target was the prediction of many kinds of biological activities from the structural formulae of chemical compounds. The PASS algorithm was based on the concept of the "biological activity spectrum", which is an intrinsic property of a compound. It reflects all its different biological activities that arise from interactions with biological entities [20] [21] [22] [23] [24] [25] [26] . It should be noted that this definition differs significantly from some other definitions of "biological activity profile" or "biological activity spectrum" published in the literature [27] [28] [29] [30] [31] , because in PASS the biological activity spectrum represents a theoretical estimate for general biological potential of the compound under study.
Biological Activities Predicted by PASS
The latest version of PASS (9.1) predicts 3750 kinds of biological activity with the average prediction accuracy of about 95% (Supplement 1). PASS could predict 3300 kinds of biological activities in 2007, 2500 activities -in 2005, 541 activities -in 1998, and only 114 activities -in 1996. Thus, the information about new biologically active compounds and novel activities is permanently collected and added into the PASS training set.
In PASS 9.1 the default list of predictable biological activities includes: 261 pharmacotherapeutic actions (e.g., anxiolytic); 66 anti-infective actions (e.g., antileishmanial); 72 actions blocking a certain process (e.g., apoptosis antagonist); 40 actions stimulated a certain process (e.g., apoptosis agonist); 140 actions blocking activity of certain endogenous substance (e.g., acetylcholine antagonist); 71 actions stimulating activity of certain endogenous substance (e.g., acetylcholine agonist); 5 actions blocking a release of a certain endogenous substance (e.g., cytochrome C release inhibitor); 9 actions stimulating a release of a certain endogenous substance (e.g., acetylcholine release stimulant); 9 actions blocking an uptake of a certain endogenous substance (e.g., adenosine uptake inhibitor); 2219 actions inhibiting a certain enzyme (e.g., 12 lipoxygenase inhibitor); 41 actions stimulating action of a certain enzyme (e.g., ATPase stimulant); 268 actions blocking a certain receptor (e.g., 5 hydroxytrypamine 1 agonist); 121 actions stimulating a certain receptor (e.g., 5 hydroxytrypamine 1 antagonist); 28 actions blocking a certain channel (e.g., chloride channel antagonist); 5 actions stimulating a certain channel (e.g., calcium channel agonist); 28 actions blocking a certain transporter (e.g., GABA transporter 1 inhibitor); 128 actions that is a substrate of a certain metabolic enzyme (e.g., CYP3A4 substrate); 24 actions inhibiting a certain metabolic enzyme (e.g, CYP3A4 inhibitor); 13 actions inducing a certain metabolic enzyme (e.g., CYP3A4 inducer); 28 actions inhibiting a certain protein (e.g., collagen inhibitor); 8 actions inhibiting an expression of a certain transcription factor (e.g., transcription factor Rho inhibitor); 2 actions stimulating an expression of a certain transcription factor (e.g., TP53 expression enhancer); 389 actions that cause a certain adverse/toxic effect (e.g., carcinogen).
In PASS we describe biological activities qualitatively ("active" or "inactive"). The qualitative presentation allows integrating the information about biologically active compounds collected from many different sources into the general PASS training set. Any property of chemical compounds, which is determined by their structural peculiarities, can be used for prediction by PASS. It is obvious, that the applicability of PASS is broader than the prediction of biological activities. For instance, this approach was successfully used for prediction of such general property of organic molecules as drug-likeness [32] .
Chemical Structure Description
We have chosen 2D structural formulae as the basis for description of chemical structure because this is the only information available at the early stage of research. Thus, using the structural formula as an input data, one can obtain the estimates of biological activity profiles even for virtual molecules, prior to their chemical synthesis and biological testing.
Many different characteristics of chemical compounds can be calculated on the basis of structural formulae [33] . In earliest versions of PASS [20, 21] we used the Substructure Superposition Fragment Notation (SSFN) codes [34] . However, SSFN, like many other structural descriptors [35] , reflects rather abstract level of chemical structure than the nature of ligand-target interactions, which are the molecular mechanisms of biological activities. The Multilevel Neighbourhoods of Atoms (MNA) descriptors [36] have certain advantages in comparison with SSFN. These descriptors are based on the molecular structure representation, which includes the hydrogens according to the valences and partial charges of other atoms and does not specify the types of bonds. MNA descriptors are generated as recursively defined sequence:
• zero-level MNA descriptor for each atom is the label A of the atom itself; • any next-level MNA descriptor for the atom is the sub-structure
where the descriptor D i of each successive level is a concatenation of the zero-level descriptor of the atom and, enclosed in parentheses, a lexicographically ordered list of descriptors of the previous level of its nearest neighbors [36] .
The atoms label may include not only the atomic type but also any additional information about the atom. In particular, if the atom is not included into the ring, it is marked by "-". The neighbour descriptors ... ... Iterative process of MNA descriptors generation can be continued covering first, second, etc. neighbourhoods of each atom.
The molecular structure is represented in PASS by the set of unique MNA descriptors of the 1 st and 2 nd levels. We consider that the substances are equivalent when they have the same set of MNA descriptors. Since MNA descriptors do not represent the stereochemical peculiarities of a molecule, the substances which structures differ only stereochemically, are formally considered as equivalent.
SAR Base
PASS estimations of biological activity spectra of new compounds are based on the structure-activity relationships data and the knowledgebase (SAR Base), which accumulates the results of the training set analysis. PASS 9.1 training set includes 205873 of the known biologically active substances (drugs, drugcandidates, pharmaceutical leads, and toxic compounds). Since new information about biologically active compounds is discovered regularly, we perform a special informational search and analyse the new information, which is further used for updating and correcting the PASS training set. SAR Base is obtained during the training procedure, which is performed using each new PASS training set.
Biological Activity Spectrum Estimation
PASS algorithm of the biological activity spectrum prediction is based on Bayesian estimates of the probabilities of a molecule belonging to the classes of active and inactive compounds, respectively. The mathematical method is described in several publications [23] [24] [25] [26] , and its details will not be discussed in this paper. Only general description necessary for interpretation of prediction results is presented here.
Since the main purpose of PASS is to predict of activity spectra of a new molecules, the general principle of the PASS algorithm is the exclusion from SAR Base the substances, which are equivalent to the substance under prediction (see above).
The structural formula of a molecule, whose prediction should be performed by PASS, is presented as a MOL file (for the set of molecules -as a SDF file). The predicted activity spectrum is presented in PASS by the list of activities with the probabilities "to be active" (Pa) and "to be inactive" (Pi) calculated for each activity. The list is arranged in descending order of Pa-Pi; therefore, more probable activities are at the top of the list. Only activities with Pa>Pi are considered as probable for a particular compound. The list can be shortened at any desirable cutoff value, but Pa>Pi is used by default. If the user chooses rather high value of Pa as a cutoff for selection of probable activities, the chance to confirm the predicted activities by the experiment is high too, but many existing activities will be lost. For instance, if Pa>90% is used as a cutoff, then about 90% of real activities will be lost; for Pa>80%, the part of lost activities is 80%, etc.
General PASS interface with representation of prediction results for a set of molecule is shown in Fig. (1) .
It is necessary to keep in mind that the probability Pa reflects the similarity of a molecule under prediction with the structures of molecules, which are the most typical in a sub-set of "actives" in the training set. Therefore, usually there is no direct correlation between the Pa values and quantitative characteristics of activities.
If the structure of active and potent compound does not resemble any typical structure of "actives" from the training set, then the Pa value calculated for such compound may be rather small (even negative Pa-Pi values could be observed). This may be explained by the following calculation. Assume that the values Pa for "active" and Pi for "inactive" are distributed uniformly, then, for instance, when Pa=0.9, then the corresponding "active" estimates are less in 90% of compounds from the training set and only in 10% these values are higher. If the investigator declines the proposition that the studied compound is active, then it leads to a wrong decision with probability 0.1. In case when Pa<0.5 and Pa > Pi, then the corresponding estimates are higher for more than a half of the "active" compounds from the training set. By declining the proposition that this compound is active, the investigator will make a wrong decision with probability less than 0.5. In such cases the probability to experimentally confirm this kind of activity is small, however, if being confirmed, this structure has a high novelty and may become NCE in more than 50% cases.
If the predicted biological activity spectrum is wide, then the structure of the compound is quite simple and does not contain peculiarities responsible for the selectivity of its biological action.
If it appears that the structure under prediction contains several new MNA descriptors (in comparison with the descriptors from the compounds of the training set), then the structure has low similarity with any structure from the training set, and the results of prediction should be considered as rough estimates.
Based on these criteria, on the basis of a compromise between the novelty of the expected pharmacological action and the risk to obtain the negative result in the experimental testing, one may choose which activities must be tested for the studied compounds. Certainly, one should also take into account a particular interest to some kinds of activities, experimental facilities, etc.
PASS Validation
Leave one out cross-validation (LOO CV) for the whole PASS 9.1 training set, which includes 205873 substances with 3750 kinds of biological activity, provides the estimates of PASS prediction accuracy during the training procedure. Average accuracy of prediction is about 95.3% according to the LOO CV estimation, while for the different kinds of activity the prediction accuracy varies from 70.7% (antineoplastic, myeloid leukemia) to 99.9% (p21-activated kinase 1 inhibitor).
The accuracy of PASS predictions depends on several factors, of which the quality of the training set seems to be the most important one. A perfect training set must include the comprehensive information about known and possible biological activities for each compound. In other words, the whole biological activity spectrum should be thoroughly investigated for each compound included into the PASS training set. Unfortunately, there is no a database with information about biologically active compounds tested against each kind of biological activities. Therefore, the information concerning the known biological activities for any compound is always incomplete.
We investigated the influence of the information's incompleteness on the prediction accuracy for new compounds. About 20000 "principal compounds" from MDDR database (SYMYX MDL) were used to create the heterogeneous training and evaluation sets. 20, 40, 60, 80% of information was randomly excluded from the training set. Either structural data or biological activity data were removed in two separate computer experiments. In both cases it was shown that even if up to 60% of information is excluded, the results of prediction are still satisfactory [37] . Thus, despite the incompleteness of information in the training set, PASS algorithm is robust enough to achieve the reasonable results of predictions.
PASS predictions were performed for about 250000 molecules from Open NCI database [38] . This information is available at the NCI web-site (http://cactus.nci.nih.gov/ncidb2/) in a searchable mode. One could combine different terms in a query using Boolean operators. For example, with a query "angiogenesis inhibitor AND Pa>0.9 AND Pi<0.2 NOT acid NOT amide" we identified 85 hits. Seven compounds were tested in NCI and four compounds showed an angiogenesis inhibitory activity in the range of 10-100 M. [38] . Also, on the basis of results of anti-HIV testing of compounds from Open NCI database, we estimated that using PASS predictions one can significantly (up to 17 times) increase the fraction of "actives" in the selected sub-set [38] .
PASS INet service (http://www.ibmc.msk.ru/PASS) provides the predictions via Internet for any registered user free of charge. It has been available since 2000 [23, 39, 40] . The input is a MOL file or drawing of a structural formula using Marvin applet. By December the 1 st , 2009 the number of registered users exceeded 5000, and over 115000 predictions were made. Based on the prediction results, the researchers select the most prospective substances for chemical synthesis and biological testing. Comparison of PASS prediction results with the experiments provides the independent validation of the approach versus compounds from different chemical series with various kinds of biological activity. Currently, over twenty publications described the coincidence of PASS predictions with the experiment. For example, due to the PASS predictions, new antileishmanial agents were found among 7-substituted 9-chloro and 9-amino-2-methoxyacridines [41] , 2 substitution-bearing 6-nitro-and 6-amino-benzothiazoles [42] , betacarboline alkaloids [43] ; new anxiolytics were found among quinazolines [44] , thiazoles, pyrazoles, isatins, a-fused imidazoles and other chemical series [45] ; new anti-inflammatory agents were found among 1-acylaminoalkyl-3,4-dialkoxybenzene derivatives [46] , substituted amides and hydrazides of dicarboxylic acids [47] ; etc. (for review -see [40] ).
Also, on the basis of PASS predictions new antihypertensive and antiinflammatory agents with dual mechanisms of actions were discovered [48, 49] , which demonstrated the capability of PASS in finding the multitargeted drugs.
PharmaExpert: Tool for Analysis of PASS Predictions
PharmaExpert [50] was developed to analyze the biological activity spectra of substances predicted by PASS. This software provides a flexible mechanism for selecting compounds with the required biological activity profiles. Different kinds of biological activities are divided into six classes: mechanisms of actions, pharmacological effects, toxic/adverse effects, metabolic terms, transporter terms and gene expression terms. Mechanism of an action reflects the interactions of biologically active compounds with biological entities at macromolecular level, for example, acetylcholinesterase inhibitor, acetylcholine release inhibitor or alpha 1 adrenoreceptor agonist. The pharmacological effect reflects the pharmacological action or pharmacotherapeutic application of the compound e.g., antiischemic, anxiolytic or Alzheimer's disease treatment. Toxic/adverse effect reflects the specific toxicity (e.g. mutagenic, teratogenic) or adverse action (arrhythmogenic, anemic, nauseant). Metabolic terms reflect interactions of chemical compounds with metabolic enzymes (e.g., CYP2D6 inhibitor, CYP3A4 substrate, CYP 2C9 inducer). Transporter terms reflect the interaction of compound with the transporters (P-glycoprotein substrate, P-glycoprotein inhibitor, P-glycoprotein inducer, etc.). Gene expression terms reflect the influence of compounds on the expression of certain genes (APOA1 expression enhancer, ErbB-2 expression inhibitor, etc.). PharmaExpert analyzes the relationships between biological activities ("mechanism-effect(s)" and "effectmechanism(s)"), identifies the probable drug-drug interactions, and searches for compounds acting on multiple targets. The analysis is based on the knowledgebase that is collected from literature during the past 10 years and includes about 8000 "mechanism-effect(s)" and "effect-mechanism(s)" relationships at present time. One example of PharmaExpert analysis is given in Fig. (2) .
PASS APPLICATIONS TO NATURAL PRODUCTS

Marine Sponge Alkaloids
We applied PASS to more than ninety marine sponges' alkaloids and their synthetic analogs (halitulin, nortoseptins, motuporamines, pyridoacrydines, aaptamines, pyrinodemins, etc.) [51] . Sixty four compounds exhibited cytotoxic activity in tumor cell lines bioassay, and they were suggested for further evaluation in vivo by NCI; all others were the novel molecules with unknown biological activities. Predicted antineoplastic activity coincided with the known experimental data in ~80% of cases (51/64). In five cases, when predictions did not correspond to the experiment, the compounds had more than two new MNA descriptors; therefore, for these compounds the reliability of predictions is low (see section 2.4).
In addition to the known antineoplastic activities, PASS predicted some new activities for these molecules. For example, we predicted a possible application of Halitulin for the treatment of psychosexual dysfunction, seborrhea, neurogenic pain and peripheral vascular disease (Fig. (3) ).
The most probable activities predicted for the analyzed set of marine sponge alkaloids include: interleukin antagonist, cerebral vasodilator, MAP kinase inhibitor, liver fibrosis treatment, 5 HT release stimulant, protein kinase inhibitor, antineoplastic; telomerase inhibitor, antineoplastic alkaloid, antiamyloidogenic, benzodiazepine 1 receptor agonist, etc. [51] . Therefore, marine sponge alkaloids represent a valuable source for finding of new biologically active compounds in many different pharmacotherapeutic areas.
Hepatoprotective Activity of Triterpenoids
Chemical modification of natural bioactive compounds often brings to the obtaining more effective substances with a different biological activity spectrum [52] . Triterpenoids of the lupane group are considered as suitable parent compounds due to (1) wide spectrum of biological activity including hepatoprotective, antibacterial, anti-inflammatory, antitumor, antiviral and other actions; (2) availability of raw materials (lupeol and betulin) extracted from white birch (Betula pendula) [53] . Thus, chemical synthesis of hemisuccinates, hemiphthalates, acetylsalicylates, cinnamates and p-metoxycinnamates of lupeol, betulin and 3-O-acetylbetulin was performed via interaction with corresponding acid anhydrides or acid chlorides. We used PASS predictions to estimate probable biological activity spectra of the synthesized compounds. For all compounds hepatoprotective activity was predicted with the reasonable probability (Pa values varied from 0.75 to 0.80). Through the subsequent biological testing of hepatoprotective action of the synthesized compounds in rats it was shown that all of them have a potent hepatoprotective effect, more potent than the extract of birch bark, betulin and reference drug silibor [53] . Betulin bis hemiphthalate demonstrated the most potent hepatoprotective effect and it was chosen for more detailed studies. Its hepatoprotective action was further confirmed in rat models of hepatitis induced by CCl 4 , ethanol and tetracycline [53] . Structural formula and predicted biological activity spectrum of betulin bishemiphthalate is shown in Fig. (4) . As one may see from this data, that no toxic/adverse effects are expected for this compound; thus, betulin bishemiphthalate could be considered as a promising lead substance. Also, in addition to the hepatoprotective effect, some other biological activities are predicted, which could be the reasons for new applications. Fig. (4) . Structural formula and predicted biological activity spectrum for Betulin bishemiphtalate (only activities predicted with Pa>0.5 are shown).
Computer-Aided Design of Macrolides with the Required Activity Profiles
Secondary metabolites produced by different organisms display diverse biological activities, thus having a potential of being pharmacological agents [54] . An example of secondary metabolites are macrolides (amphotericin, nystatin, erythromycin, methymycin etc.), produced mainly by bacteria and some fungi. Macrolides display a wide range of biological activities, including antibacterial, antifungal, antiviral, immunosuppressive, antineoplastic etc. [55] . Macrolides are biosynthetically assembled by the modular polyketide synthase (PKS) enzymes [56] (example of erythromycin synthesis see in Fig. (5) ).
Mode of action of PKS theoretically leads to an extremely large number of analogues, which can be produced upon combinatorial manipulation with these enzymes. Experimental engineering of all possible variants of a certain PKS system as well as isolation and testing of the resulting macrolides in the laboratory are unfeasible. Due to the achievements in postgenomic technologies, rational approach can be applied to design of the macrolides' structures based on the information on their biosynthesis. Mode of action of PKS can be simulated in silico, thus leading to the generation of virtual libraries of macrolide's analogues [57] . Such combinatorial libraries can be analyzed using computer-aided prediction of biological activities, physico-chemical properties, drug-likeness etc., and yielding compounds with the desired properties. This approach provides rational selection of macrolide's molecules with the desired biological activities.
To perform a rational design of new polyketides with the required biological activity spectrum we developed BioGenPharm software, which generates combinatorial libraries of polyketides based on the user-defined input parameters, performs PASS predictions of biological activity spectra for the generated structures, and PharmaExpert selection of molecules with the required properties [58] . Validation of PASS prediction ability for polyketides was carried out against the test set containing 242 natural macrolides from the Dictionary of Natural Products [59] . The mean prediction accuracy was 75.5% [58] .
We show applicability of the proposed approach by generation of a virtual library of the erythromycin analogues and by selection of substances with low probability of the hepatotoxic effect. Erythromycin is reasonably well tolerated by patients; the most serious side-effect observed during administration of all pharmaceutical forms of erythromycin is cholestasis [60] . Administration of erythromycin may also cause the increase of serum transaminases and the development of cholestatic hepatitis. The mechanism of toxic liver damage by erythromycin administration remains unclear: it was shown that erythromycin does not inhibit bile acids (taurocholic acid) transport [61] . We have searched for erythromycin analogues, whose hepatotoxic activity was predicted with a minimal probability. The erythromycin analogues library was generated using the following set of parameters: propionate starter, 6 extender modules, and cladinose glycosylation by the 3rd carbon atom, desosamine glycosylation by the 5th carbon atom, hydroxylation by the 6th and 12th carbon atom. Compounds were selected at Pa>0.8 and Pa<0.6 for antibacterial and hepatotoxic activities, respectively.
As a result, we obtained 17 erythromycin analogues which satisfy all the criteria settings. Among them, the lowest probability of hepatotoxic activity and the highest probability of antibacterial activity were observed for a molecule No. 2456. Hepatotoxic activity was predicted for this compound with Pa=56.5%, while for erythromycin hepatotoxicity was predicted with Pa=94.1%; thus, the most perspective erythromycin analogue was a compound No. 2456. The information on domain composition of PKS required for biosynthesis, necessary for the design of corresponding microorganism-producer, was obtained with BioGenPharm program (Fig.  (6) ).
IN SILICO ANALISIS OF HYPERICUM PERFORATUM AS A HERBAL MEDICINE
We selected one of the most popular herbal medicines St John's Wort (Hypericum perforatum) as an example for the case study. In this study, using PASS and PharmaExpert we estimated in silico the most probable pharmacological mechanisms and effects that could be expected for individual components of St John's Wort (SJW), likely interactions between the components in extracts, possible peculiarities in pharmacological action of herbs collected in different areas. SJW is mainly used in clinical practices for the treatment of a mild or moderate depression. In Germany, St John's Wort is the leading treatment against depression, outselling Fluoxetine (Prozac®) [62] . The main advantage of this herb, which promoted its wide use, is less side effects in comparison with traditional antidepressants (Fig. (7) ).
SJW is also recommended for the treatment of bacterial and viral infections, skin wounds, tumor, peptic ulcers and inflammation; it has antiseptic, choleretic, spasmolytic, analgesic, antioxidant and photosensitive activities [62] [63] [64] . These pharmacotherapeutic effects and SJW interactions with the drugs, mainly on CYP3A4 level, is the reason for an intensive study of both constituents of the extract and their biological activity. Using "St John's Wort" as a keyword one can find about 2000 articles in PubMed.
Numerous biologically active constituents were identified in St John's Wort, including naphthodianthrones (e.g. hypericin and its derivatives), phloroglucinols derivatives (e.g. hyperforin) and flavonoids (e.g. rutin, quercetin, quercitrin and biapigenin) [63] . Hypericum perforatum is widely distributed herb. It grows in America, Europe, Asia, Africa and Australia. Some of the extract components may be different depending on the region. This may influence on both therapeutic and side effects of SJW extracts. Therefore, the knowledge of probable activity of each component and the interaction between them is important for estimating the clinical usage of St John's Wort obtained from different places. Such information could be obtained by computer prediction of biological activity spectra with PASS.
General Analysis of Individual Constituents in St John's Wort
We have found available information about ninety three compounds, which were determined in St John's Wort collected from different regions (Supplement 2). The basic compounds represented in the majority of studied extracts of Hypericum perforatum include: hyperforin, hypericin, pseudohypericin, rutin, quercetin, quercitrin, isoquercitrin, biapigenin, alpha-pinene, hyperoside and chlorogenic acid. Information on the known biological activities collected from the main reviews of St John's Wort compositions and contained in PASS training set is also provided in Supplement 2.
Prediction of biological activity spectra for all 93 compounds was carried out with PASS 9.1. The distribution of predicted activities' number for 93 compounds depending on the predicted probability is shown in Fig. (8) . Fig. (8) shows that 817 from 3750 biological activities, which can be predicted by PASS, are expected with probability Pa>0.7 at least for one constituent from the St John's Wort extract. The number of compounds with a particular amount of predicted activities (N) is shown in Fig. (9) . It is clear that at the cutoff Pa>0.7 maximum of distribution is located at N=10. Also, about 38% of compounds have no more than 20 activities predicted with Pa>0.7, however over 45% of compounds have more than 40 predicted activities. It means that only a small part of compounds exhibit some selectivity, while the majority of St John's Wort constituents are multitargeted agents.
Prediction of Pharmacotherapeutic Effects
Pharmacotherapeutic effects predicted at least for one of the analyzed compounds with Pa>0.5 (analgesic and antiviral activities -with less probability Pa>0.4) are listed in Table 1 . Also, in Table 1 one could find the IDs of compounds designated according to the Supplement 2. The IDs allow to label the compounds exhibiting particular kinds of activity (IDs are arranged in the descending order of probability of the appropriate activity). Table 1 shows that Fig. (9) . Amount of compounds from St John's Wort, which have a particular number of predicted activities at different thresholds (A -Pa>0.5; B -Pa>0.7). the most frequent activities predicted for SJW constituents are antioxidant, antiinflammatory, antineoplastic, choleretic, and antiulcerative.
Prediction of Side Effects
As was mentioned above, St John's Wort reveals fewer side effects in comparison with the traditional antidepressants. Analyzing the prediction of biological activity spectra for 93 SJW constituents, one may determine the compounds probably causing particular side effects. The most frequent side effects of St John's Wort mentioned in [62] are shown in Table 2 . This data could be compared with the appropriate predictions obtained with the special version of PASS trained using information on the known side effects of drugs [60] . All known side effects have been predicted except for the Gastrointestinal symptoms, which are not covered by this version of PASS (PASS terms used in Table 2 sometimes synonymous to the names of adverse effects from [62] ). Moreover, PASS predictions help to identify the compound(s), which likely have a particular side effect. Such information may be useful in further studies of individual components of SJW as a potential pharmaceutical leads. 
Prediction of Probable Interactions Between the St John's Wort Constituents
Each compound in St John's Wort has a unique profile of biological activity. The total number of predicted activities for ninety three compounds grouped according to the activity types is represented in Fig. (10) . When the St John's Wort is administered to patients in clinics or to experimental animals in preclinical studies, the individual compounds interact with each other pharmacologically that could lead to both positive and negative manifestations. The analysis of predicted biological activity spectra for individual compounds, which can be performed on the basis of knowledge about mechanism-effect relationships, reveals the possible interactions. If either a particular mechanism of action or a few mechanisms of action causing the same pharmacotherapeutic of toxic/side effect were predicted for several compounds, then such interaction could lead to additive/synergistic activity. If several compounds have different mechanisms, which lead to an opposite to pharmacotherapeutic toxic/side effect, then such interaction could lead to the antagonistic activity. The total number of predicted interaction at cutoff Pa>0.7 is given in Fig. (11) . Fig. (11) shows that multiple potential interactions could be found at each of four activity types (mechanisms, pharmacotherapeutic effects, toxic/side actions, and metabolism). All possible additive/synergistic interactions and their causes identified by PharmaExpert at cutoff Pa>0.7 are presented in Table  1 (Supplement 3). As one can see from this data, the basic known pharmacotherapeutic effects could be caused by additive/synergistic action of different components of St John's Wort. Based on this analysis, several new pharmacotherapeutic effects caused by additive or synergistic action were also identified (e.g. atherosclerosis treatment, antipsoriatic, neuroprotector, etc.). These findings should be checked in further experimental studies.
We have identified several additive/sinergistic interactions leading to toxic/effects ( Supplement 3) can be used either for excluding these components from the extracts or for collecting the Hypericum perforatum in the regions, where the fraction of these components in the herb is either absent or small. Data on additive/synergistic or antagonistic effects at the level of metrabolism should also be taken into account at dosage determining, particularly, in combination therapy.
We also found 142 possible interactions of St John's Wort constituents at the level of molecular mechanisms of action. This data is partially given in Table 4 (Supplement 3). Interaction at the level of molecular mechanisms could also lead to additive/ synergistic or antagonistic effects.
Prediction of Likely Different Actions in St John's Worts Collected in Different Regions
The analysis of predicted biological activity spectra may reveal the features in clinical manifestations of plant extracts prepared using raw materials collected in different geographical regions. This could be illustrated by comparison of essential oils' compositions from Hypericum perforatum collected in Southeastern Serbia [65] and Lithuania [66] . The essential oil compositions from Southeastern Serbia and Lithuania contain 14 and 19 compounds, respectively. Six compounds with IDs 11, 35, 43, 46, 47 and 59 (Supplement 2) are identical. Table 3 demonstrates the difference between the predicted activities for the samples from the Southeastern Serbia and Lithuania. While the total numbers of mechanisms of action and toxic effects are similar for both sets, the significant difference is observed in therapeutic effects and interactions with drug-metabolizing enzymes. More detailed analysis of predicted toxic/side effects showed that, despite the qualitative identity of the effects predicted for the both sets, the number of compounds that could reveal these effects is different (Table 4) . Hematotoxic, hyperthermic, neurotoxic effects and the inhibition of thrombo-cytopoiesis were predicted for more compounds from essential oil from Serbia. At the same time emetic and reproductive dysfunction effects were predicted for more compounds from essential oil from Lithuania.
The detailed analysis of prediction of the studied subsets interactions with drug-metabolic enzymes shows that the majority of predicted interactions are the same ( Table 5) . CYP17 inhibition and CYP2C19 induction only were not predicted for the samples from Southeastern Serbia. The number of compounds predicted as the inducers of CYP2B6 and inhibitors of CYP2B6 and CYP2C8 for essential oil composition from Serbia exceeded those from Lithuania.
Prediction of biological activity spectra for the two sets of compounds and further analysis of possible interactions between the constituents determined the difference in additive/synergistic pharmacotherapeutic effects for essential oil compositions from Serbia and Lithuania. Table 6 shows that the essential oil compositions from Southeastern Serbia and Lithuania have 25 identical additive/synergistic pharmacotherapeutic effects. At the same time, seven additive/synergistic therapeutic effects (antidote, cyanide; antihypoxic; antiinflammatory, intestinal; antimutagenic; antineurotic; cytoprotectant and sialagogue) were predicted for the sample from Serbia only. The other eleven additive/synergistic therapeutic effects were predicted for the sample from Lithuania only ( Table 6 ). Such information could help to estimate the clinical potential of plant extracts collected from different geographical regions.
FUTURE TASKS
In this review we presented some examples of how computeraided prediction of biological activity spectra could be used for the analysis of pharmacotherapeutic potential of natural products. More examples can be found in our papers [67] [68] [69] [70] [71] [72] [73] . The prediction results for the individual constituents identified in herbs, sponges, microorganisms etc. could reveal the hidden potentials of natural products by identification of active substances that caused the effects known from ethnopharmacology and molecular mechanisms of their action. The predicted biological activity spectra provide the basis for new rational combinations of medicinal plants with improved efficacy and safety, as well as the recommendations for the personalization of therapy. This information can also be used for selecting new pharmaceutical leads with the required biological activity profiles [12, 50, [74] [75] [76] .
The accuracy of biological activity spectra prediction strongly depends on three issues: (1) robustness of the algorithm for the analysis of structure-activity relationships, (2) its orientation on prediction of biological activity of novel molecules, and (3) quality of the training set. The first two issues were thoroughly investigated and implemented in PASS. To provide more reliable estimates, we are permanently collecting new information about biologically active compounds, add it to the training set and update the PASS knowledgebase. Further development of the algorithm [77] and the increase of quantitative data available for the training set provide the possibility to switch from SAR to QSAR analysis.
Certainly, for a more detailed analysis of the multitargeted action of compounds and their interactions, it is necessary to apply the computational methods simulating the behavior of regulatory pathways under treatment by individual pharmaceutical agents and their combinations. Such methods are currently developed by our team [78] and by some other researchers [79, 80] . 
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